VR Adviser, LLC - Q4 2021 holdings

$732 Million is the total value of VR Adviser, LLC's 26 reported holdings in Q4 2021. The portfolio turnover from Q3 2021 to Q4 2021 was 50.0% .

 Value Shares↓ Weighting
TVTX BuyTravere Therapeutics Inc$61,925,000
+47.4%
1,994,997
+15.2%
8.46%
+56.9%
RLMD BuyRelmada Therapeutics Inc$51,145,000
+40.6%
2,270,072
+63.6%
6.99%
+49.6%
GHRS BuyGH Research PLCord sh$47,173,000
+30.2%
2,021,985
+23.1%
6.45%
+38.6%
VRDN BuyViridian Therapeutics Inc$36,632,000
+11311.8%
1,852,919
+9404.6%
5.01%
+12114.6%
BuyMarinus Pharmaceuticals Inc$34,216,000
+13.8%
2,880,096
+9.0%
4.68%
+21.1%
TCDA BuyTricida Inc$33,411,000
+1742.9%
3,494,851
+794.5%
4.57%
+1860.1%
NewLianBiospons adr$33,131,0005,378,341
+100.0%
4.53%
KDNY NewChinook Therapeutics Inc$20,939,0001,283,821
+100.0%
2.86%
AFMD NewAffimed NV$7,886,0001,428,571
+100.0%
1.08%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2022-02-14
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
ACLARIS THERAPEUTICS INC12Q3 202312.7%
VIRIDIAN THERAPEUTICS INC12Q3 202313.4%
COGENT BIOSCIENCES INC12Q3 202310.3%
RELMADA THERAPEUTICS INC11Q3 20229.9%
GH RESEARCH PLC10Q3 20236.7%
ALTIMMUNE INC9Q3 202211.6%
MARINUS PHARMACEUTICALS INC9Q4 20225.7%
CELLDEX THERAPEUTICS INC9Q3 20227.6%
AFFIMED N V8Q3 20231.1%
INSTIL BIO INC7Q3 202218.7%

View VR Adviser, LLC's complete holdings history.

Latest filings
TypeFiled
13F-HR2024-02-14
13F-HR2023-11-14
13F-HR2023-08-11
13F-HR/A2023-05-15
13F-HR/A2023-05-15
13F-HR/A2023-05-15
13F-HR2023-05-15
13F-HR2023-02-14
13F-HR2022-11-14
13F-HR2022-08-15

View VR Adviser, LLC's complete filings history.

Compare quarters

Export VR Adviser, LLC's holdings